文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

1 型糖尿病患儿树突状细胞吞噬功能受损,但不影响其免疫耐受潜能。

Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential.

机构信息

Immunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, Spain.

Pediatrics Section, Germans Trias i Pujol University Hospital, Badalona, Spain.

出版信息

Front Immunol. 2019 Nov 28;10:2811. doi: 10.3389/fimmu.2019.02811. eCollection 2019.


DOI:10.3389/fimmu.2019.02811
PMID:31849983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6892968/
Abstract

Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to autoimmunity. Countless factors can potentially impact on the proper functionality of the DCs, which range from altered subset distribution, impaired phagocytic function to abnormal gene expression. Moreover, in T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D clinical course is likely to be more aggressive in children and adolescents and entails severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations in pediatric T1D at different stages, as well as to characterize their phagocytosis ability and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D, with established disease and control subjects were recruited. Firstly, DCs subsets from peripheral blood were found quantitatively altered during the first year of disease, but recovered in the second year of progression. Secondly, to study the tolerogenic functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic apoptotic beta cells, which are able to induce tolerance, as previously demonstrated by our group in DCs from adult patients with T1D. In this study, monocyte-derived DCs from pediatric patients with T1D and control subjects were assessed in terms of PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less efficiently than DCs from control subjects, inversely correlating with disease evolution. Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine profile, and membrane expression of immunological markers in DCs was consistent with tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs phagocytosis, although tolerance induction could still function optimally. Therefore, this study provides useful data for patient follow-up and stratification in immunotherapy clinical trials.

摘要

1 型糖尿病(T1D)是由免疫耐受缺陷引起的,树突状细胞(DCs)在免疫反应中起着至关重要的作用。事实上,它们有助于维持对自身抗原的耐受性,但也可以引发针对自身抗原的免疫反应,导致自身免疫。无数因素可能会影响 DCs 的正常功能,包括亚群分布改变、吞噬功能受损到异常基因表达等。此外,在 T1D 中,代谢失调也可能损害 DC 的功能。事实上,由于 T1D 临床病程在儿童和青少年中可能更为激进,并且涉及严重的糖代谢紊乱,因此本研究旨在分析不同阶段儿科 T1D 患者循环 DC 亚群,并对其吞噬能力和诱导耐受的能力进行特征分析。因此,招募了新诊断为 T1D 的儿科患者、疾病已确诊的患者和对照组患者。首先,发现疾病发生后的第一年外周血中的 DC 亚群数量发生了改变,但在病程的第二年恢复正常。其次,为了研究 DC 的耐受功能,设计了含有磷脂酰丝氨酸(PS)的脂质体来模拟凋亡的β细胞,正如我们之前在成人 T1D 患者的 DC 中所证明的那样,凋亡的β细胞能够诱导耐受。在这项研究中,我们评估了来自儿科 T1D 患者和对照组患者的单核细胞来源的 DC 对 PS 脂质体的摄取动力学以及转录和表型变化。与对照组相比,T1D 患儿的 DC 摄取 PS 脂质体的速度较慢且效率较低,与疾病进展呈负相关。尽管如此,PS 受体和免疫调节基因的转录、细胞因子谱以及 DC 表面免疫标志物的表达与 PS 脂质体吞噬后的耐受诱导潜能一致。总之,儿童时期 T1D 的进展导致外周血 DC 亚群改变以及 DC 吞噬功能受损,尽管诱导耐受仍能发挥最佳功能。因此,本研究为免疫治疗临床试验中的患者随访和分层提供了有用的数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/9698599ab8b2/fimmu-10-02811-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/c6c57be8f665/fimmu-10-02811-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/0fc8e8ac3f1d/fimmu-10-02811-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/6dd684121d9b/fimmu-10-02811-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/24bac0f34155/fimmu-10-02811-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/9698599ab8b2/fimmu-10-02811-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/c6c57be8f665/fimmu-10-02811-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/0fc8e8ac3f1d/fimmu-10-02811-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/6dd684121d9b/fimmu-10-02811-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/24bac0f34155/fimmu-10-02811-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b27/6892968/9698599ab8b2/fimmu-10-02811-g0005.jpg

相似文献

[1]
Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential.

Front Immunol. 2019-11-28

[2]
Phosphatidylserine-Liposomes Promote Tolerogenic Features on Dendritic Cells in Human Type 1 Diabetes by Apoptotic Mimicry.

Front Immunol. 2018-2-14

[3]
Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes.

J Autoimmun. 2024-5

[4]
Increased density of tolerogenic dendritic cells in the small bowel mucosa of celiac patients.

World J Gastroenterol. 2015-1-14

[5]
Stat5b/Ezh2 axis governs high PD-L1 expressing tolerogenic dendritic cell subset in autoimmune diabetes.

Int Immunopharmacol. 2024-5-30

[6]
Constitutively active Stat5b signaling confers tolerogenic functions to dendritic cells of NOD mice and halts diabetes progression.

J Autoimmun. 2016-9-12

[7]
FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children.

Front Immunol. 2019-1-22

[8]
Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes.

Clin Exp Immunol. 2009-12-17

[9]
Altered Frequency and Phenotype of HLA-G-Expressing DC-10 in Type 1 Diabetes Patients at Onset and in Subjects at Risk to Develop the Disease.

Front Immunol. 2021

[10]
Regulation of Tolerogenic Features on Dexamethasone-Modulated MPLA-Activated Dendritic Cells by MYC.

Front Immunol. 2019-5-28

引用本文的文献

[1]
Tissue Resident and Infiltrating Immune Cells: Their Influence on the Demise of Beta Cells in Type 1 Diabetes.

Biomolecules. 2025-3-19

[2]
Toward a cure for type 1 diabetes: the innovative potential of Phosphatidylserine-rich liposomes.

Nanomedicine (Lond). 2025-5

[3]
Evaluation of serum vitamin D metabolites, phagocytosis, and biomarkers of inflammation in dogs with naturally occurring diabetes mellitus.

Front Vet Sci. 2024-8-21

[4]
Ex Vivo Immune Function and Modulatory Effects of Calcitriol in Dogs with Naturally Occurring Diabetes Mellitus.

Vet Sci. 2024-4-28

[5]
Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.

Front Immunol. 2023

[6]
Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus.

BioDrugs. 2023-5

[7]
Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes.

Front Immunol. 2022

[8]
Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application.

Drug Deliv. 2021-12

[9]
Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes.

World J Diabetes. 2021-5-15

[10]
Islet-Resident Dendritic Cells and Macrophages in Type 1 Diabetes: In Search of Bigfoot's Print.

Front Endocrinol (Lausanne). 2021

本文引用的文献

[1]
Changes in innate and adaptive immunity over the first year after the onset of type 1 diabetes.

Acta Diabetol. 2019-9-30

[2]
Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective.

Front Immunol. 2019-2-22

[3]
Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy.

Front Immunol. 2019-2-6

[4]
Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study.

Diabetologia. 2018-11-28

[5]
Silencing LAIR-1 in human THP-1 macrophage increases foam cell formation by modulating PPARγ and M2 polarization.

Cytokine. 2018-8-31

[6]
The Role of Efferocytosis in Autoimmune Diseases.

Front Immunol. 2018-7-20

[7]
Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?

Diabetes. 2018-8

[8]
Phosphatidylserine-Liposomes Promote Tolerogenic Features on Dendritic Cells in Human Type 1 Diabetes by Apoptotic Mimicry.

Front Immunol. 2018-2-14

[9]
Macrophage Clearance of Apoptotic Cells: A Critical Assessment.

Front Immunol. 2018-1-30

[10]
Apoptotic Cells Induced Signaling for Immune Homeostasis in Macrophages and Dendritic Cells.

Front Immunol. 2017-10-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索